Literature DB >> 20507208

Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.

Weerawat Manosuthi, David M Butler, Wasun Chantratita, Chonlaphat Sukasem, Douglas D Richman, Davey M Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20507208      PMCID： PMC2982719          DOI： 10.1089/aid.2009.0107

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  16 in total

1.  Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission.

Authors:  Davey M Smith; Joseph K Wong; Hai Shao; George K Hightower; Stephanie H T Mai; Joseph M Moreno; Caroline C Ignacio; Simon D W Frost; Douglas D Richman; Susan J Little
Journal:  J Infect Dis       Date:  2007-06-19       Impact factor: 5.226

2.  Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.

Authors:  Giuseppe Lapadula; Alessandra Calabresi; Filippo Castelnuovo; Silvia Costarelli; Eugenia Quiros-Roldan; Giuseppe Paraninfo; Francesca Ceresoli; Franco Gargiulo; Nino Manca; Giampiero Carosi; Carlo Torti
Journal:  Antivir Ther       Date:  2008

3.  TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.

Authors:  Johan Vingerhoets; Hilde Azijn; Els Fransen; Inky De Baere; Liesbet Smeulders; Dirk Jochmans; Koen Andries; Rudi Pauwels; Marie-Pierre de Béthune
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.

Authors:  Joris Hemelaar; Eleanor Gouws; Peter D Ghys; Saladin Osmanov
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

5.  Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.

Authors:  L T Bacheler; E D Anton; P Kudish; D Baker; J Bunville; K Krakowski; L Bolling; M Aujay; X V Wang; D Ellis; M F Becker; A L Lasut; H J George; D R Spalding; G Hollis; K Abremski
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

Authors:  Martin S Hirsch; Huldrych F Günthard; Jonathan M Schapiro; Françoise Brun-Vézinet; Bonaventura Clotet; Scott M Hammer; Victoria A Johnson; Daniel R Kuritzkes; John W Mellors; Deenan Pillay; Patrick G Yeni; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2008-07-15       Impact factor: 9.079

7.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

Authors:  Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christine Katlama; Arend Moll; William Towner; Benoit Trottier; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Benny Baeten; Greet Beets; Rekha Sinha; Brian Woodfall
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

8.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

Authors:  José Valdez Madruga; Pedro Cahn; Beatriz Grinsztejn; Richard Haubrich; Jacob Lalezari; Anthony Mills; Gilles Pialoux; Timothy Wilkin; Monika Peeters; Johan Vingerhoets; Goedele de Smedt; Lorant Leopold; Roberta Trefiglio; Brian Woodfall
Journal:  Lancet       Date:  2007-07-07       Impact factor: 79.321

Review 9.  Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection.

Authors:  Clare L Booth; Anna Maria Geretti
Journal:  J Antimicrob Chemother       Date:  2007-04-19       Impact factor: 5.790

10.  Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1.

Authors:  Sergei L Kosakovsky Pond; Davey M Smith
Journal:  Clin Infect Dis       Date:  2009-05-01       Impact factor: 9.079
View more
  10 in total

1.  Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations.

Authors:  Shanmugam Saravanan; Vidya Madhavan; Rami Kantor; Sathasivam Sivamalar; Selvamurthi Gomathi; Sunil S Solomon; Nagalingeswaran Kumarasamy; Davey M Smith; Robert T Schooley; Suniti Solomon; Pachamuthu Balakrishnan
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-21       Impact factor: 2.205

2.  Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.

Authors:  Eugene L Asahchop; Mark A Wainberg; Richard D Sloan; Cécile L Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

3.  Extensive drug resistance in HIV-infected Cambodian children who are undetected as failing first-line antiretroviral therapy by WHO 2010 guidelines.

Authors:  Mia Coetzer; Benjamin Westley; Allison Delong; Chhraing Tray; Dim Sophearin; Eric Nerrienet; Leeann Schreier; Rami Kantor
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-27       Impact factor: 2.205

4.  Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.

Authors:  Eugene L Asahchop; Maureen Oliveira; Mark A Wainberg; Bluma G Brenner; Daniela Moisi; Thomas d'Aquin Toni; Cecile L Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

5.  Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.

Authors:  Ujjwal Neogi; Anita Shet; Ranjani Shamsundar; Maria L Ekstrand
Journal:  AIDS       Date:  2011-05-15       Impact factor: 4.177

6.  Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Authors:  Nicole Ngo-Giang-Huong; Gonzague Jourdain; Billy Amzal; Pensiriwan Sang-a-gad; Rittha Lertkoonalak; Naree Eiamsirikit; Somboon Tansuphasawasdikul; Yuwadee Buranawanitchakorn; Naruepon Yutthakasemsunt; Sripetcharat Mekviwattanawong; Kenneth McIntosh; Marc Lallemant
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

Review 7.  The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.

Authors:  Mark A Wainberg
Journal:  Scientifica (Cairo)       Date:  2012-12-31

8.  Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes.

Authors:  Austin Huang; Joseph W Hogan; Xi Luo; Allison DeLong; Shanmugam Saravanan; Yasong Wu; Sunee Sirivichayakul; Nagalingeswaran Kumarasamy; Fujie Zhang; Praphan Phanuphak; Lameck Diero; Nathan Buziba; Sorin Istrail; David A Katzenstein; Rami Kantor
Journal:  Open Forum Infect Dis       Date:  2015-11-03       Impact factor: 3.835

9.  The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.

Authors:  Karen Schneider; Chidi Nwizu; Richard Kaplan; Jonathan Anderson; David P Wilson; Sean Emery; David A Cooper; Mark A Boyd
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

10.  High prevalence of PI resistance in patients failing second-line ART in Vietnam.

Authors:  Vu Phuong Thao; Vo Minh Quang; Jeremy N Day; Nguyen Tran Chinh; Cecilia M Shikuma; Jeremy Farrar; Nguyen Van Vinh Chau; Guy E Thwaites; Sarah J Dunstan; Thuy Le
Journal:  J Antimicrob Chemother       Date:  2015-12-11       Impact factor: 5.790
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.